logo
logo

Erasca Extends Series B Financing to $236 Million

Erasca Extends Series B Financing to $236 Million

08/31/20, 12:03 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgsan diego
Money raised
$236 million
Round Type
series b
Erasca, a company whose mission is to erase cancer, today announced the completion of a $36 million extension of its Series B financing round, which brings the total round to $236 million. New investors include Partner Fund Management and OrbiMed.

Company Info

Company
Erasca
Location
san diego, california, united states
Additional Info
At Erasca, our mission is embedded in our name: To erase cancer. Energized by recent scientific discoveries in drugging various biological drivers of cancer, we are advancing multiple programs that shut down key cancer pathways in order to solve oncology’s hardest problems. We have assembled a proven team and joined forces with world-class collaborators who embrace our ambitious goals. We also are pursuing additional pipeline expansion opportunities through academic and biopharmaceutical collaborations. Founded in 2018 and headquartered in San Diego, Erasca has raised $300 million in financing from investors who share the company’s bold mission, including ARCH Venture Partners, City Hill Ventures and Cormorant Asset Management. For more information, please visit www.erasca.com.